ADC Market Dynamics: Trends, Challenges, and Opportunities in Antibody Drug Conjugates

Antibody Drug Conjugates (ADC) Market in terms of revenue was estimated to be worth $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028, growing at a CAGR of 15.2% from 2023 to 2028 according to a new report by MarketsandMarkets™.

The major factors driving the growth of the market are collaborations partnerships among market players operating in the market, increasing focus on the development of new ADCs and frequent approval from the FDA for new ADCs. Robust products under clinical studies and increased use of ADCs as combination therapy are likely to uplift market growth in coming years.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857391

Browse in-depth TOC on “Antibody Drug Conjugates (ADC) Market”

260 - Tables

43 - Figures

283 - Pages

Antibody Drug Conjugates (ADC) Market Scope:

Report Coverage

Details

Market Revenue in 2023

$9.7 billion

Estimated Value by 2028

$19.8 billion

Growth Rate

Poised to grow at a CAGR of 15.2%

Market Size Available for

2021-2028

Forecast Period

2023-2028

Forecast Units

Value (USD Billion)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

Segments Covered

By Product, By Disease Type, By Linker type, By Target, By Payload Type

Geographies Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Report Highlights

Updated financial information / product portfolio of players

Key Market Opportunities

Adoption of combination therapies

Key Market Drivers

Increased investment and collaborations by key market players for the development of novel ADCs

The Kadcyla segment dominated the market in 2022.

Based on product, the global antibody drug conjugates market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy and others. In 2022, the Kadcyla held a dominant share owing to rise in the prevalence of cancer and increased use of ADCs for the treatment of cancer, which is one of the major factors driving the segmental growth. Furthermore, increased approvals for various disease indications for adcertis are likely to drive segmental growth in coming years.

The breast cancer segment accounted for the largest share of the disease type segment in the antibody drug conjugates market in 2022.

The breast cancer segment is the fastest growing segment and accounted for the largest share of the market in 2022. The large share of this segment can be attributed increasing prevalence of breast cancer across the globe. The launch of biosimilars is further likely to have a positive impact on segmental growth. For instance, in May 2021, Zydus launched Ujvira, the first antibody drug conjugate (ADC) biosimilar for treating both early and advanced HER2-positive breast cancer.

The Asia Pacific region will be the fastest-growing region of the antibody drug conjugates market in 2022.

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the antibody drug conjugates markets in the region is driven by a rising emphasis on strategic initiatives such as partnerships, collaborations expansion and increased adoption of ADCs among the patent population. The rising prevalence of cancer and increased investment in research development of the launch of novel ADCs in the region are some of the major factors anticipated to upsurge the market growth.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=122857391

Antibody Drug Conjugates (ADC) Market Dynamics:

Drivers:

Rising incidence of cancer
Increasing investments for ADC development
Growing number of ADCs in clinical trials
Favorable regulatory support
Restraints:

High manufacturing costs
Side effects associated with ADCs
High attrition rate in product development
Opportunities:

Adoption of combination therapies
High growth in emerging economies
Emergence of advanced ADCs
Challenge:

Technical complexities
Key Market Players of Antibody Drug Conjugates Industry:

The antibody drug conjugates market is competitive, with a small number of players competing for market shares. F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), and Zydus Group (India), among others are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Recent Developments:

In July 2023, ImmunoGen, Inc., entered into a multi-target license and option agreement with ImmunoBiochem to develop next-generation antibody-drug conjugates.
In July 2023, BeiGene and DualityBio entered into a partnership to advance differentiated antibody drug conjugate (ADC) therapy for solid tumors.
In June 2023, Lonza acquired Synaffix B.V. a biotechnology company involved in commercializing clinical-stage technology platforms for the development of antibody drug conjugates.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=122857391

Research Insight: https://www.marketsandmarkets.com/ResearchInsight/antibody-drug-conjugates-market.asp

Content Source: https://www.marketsandmarkets.com/PressReleases/antibody-drug-conjugates.asp